medigraphic.com
ISSN 0016-3813 (Print)

2016, Number 5

<< Back Next >>

Gac Med Mex 2016; 152 (5)

Manifestaciones cutáneas en enfermedad inflamatoria intestinal

Chavez-Álvarez S, Gómez-Flores M, Ocampo-Candiani J

Language: Spanish
References: 52
Page: 622-630
PDF size: 279.00 Kb.


ABSTRACT

Inflammatory bowel disease (IBD), mainly chronic unspecific ulcerative colitis and Crohn’s disease have increased in incidence in the last decades. These have multiple extraintestinal manifestations, with those of the skin appearing after the intestinal clinical presentation. These are classified as: granulomatous dermatosis, reactive dermatosis, and those secondary to treatment of IBD, and other dermatosis. This article presents the pathogenesis, clinical approach, treatment and expected evolution of these manifestations.


REFERENCES

  1. Orholm M, Munkholm P, Langholz E, Nielsen OH, Sørensen TI, Binder V. Familial occurrence of inflammatory bowel disease. N Engl J Med. 1991;324(2):84-8. Tabla 4. Manifestaciones cutáneas secundarias a medicamentos Medicamento Dermatosis secundarias Anti-TNF Granuloma anular, dermatitis reaccional medicamentosa, vasculitis leucocitoclástica, LES, psoriasis, lesiones eccematosas, carcinoma escamocelular o linfoma de células T o B10,16,51. Azatioprina Dermatitis reaccional medicamentosa, urticaria, angioedema, prurito o carcinoma escamocelular16,52. Ciclosporina Hiperplasia gingival, acné, verrugas virales, hiperplasias sebáceas, púrpura, vasculitis leucocitoclástica, carcinoma escamocelular o linfoma16,25. Esteroides Infección cutánea, reacción acneiforme, atrofia, telangiectasias, estrías, redistribución de la grasa o hipertricosis10,16,25. 6-mercaptopurina Alopecia, hiperpigmentación de piel y uñas, úlceras de mucosa oral o carcinoma escamocelular16,52. Metotrexato Úlceras en mucosa oral y piel, NET, acné, onicolisis, fototoxicidad, pseudolinfoma o carcinoma escamocelular16. Sulfasalazina/ Mesalazina/ Sulfapiridina Liquen plano, urticaria, vasculitis16.

  2. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore). 1976;55(5):401-12.

  3. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol. 1996;23(1):29-34.

  4. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427-34.

  5. Thrash B, Patel M, Shah KR, Boland CR, Menter A. Cutaneous manifestations of gastrointestinal disease: part II. J Am Acad Dermatol. 2013;68(2):211. e1-33; quiz 244-6.

  6. Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106(1):110-9.

  7. Geng X, Biancone L, Dai HH, et al. Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology. 1998;114(5):912-22.

  8. Moravvej H, Razavi GM, Farshchian M, Malekzadeh R. Cutaneous Manifestations in 404 Iranian Patients With Inflammatory Bowel Disease: A Retrospective Study. Indian J Dermatol Venereol Leprol. 2009;74(6): 607-10.

  9. Farhi D, Cosnes J, Zizi N, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine (Baltimore). 2008;87(5):281-93.

  10. Huang BL, Chandra S, Shih DQ. Skin manifestations of inflammatory bowel disease. Front Physiol. 2012;3:13.

  11. Ott C. Extraintestinal manifestations and complications in IBD. Nature reviews. Gastroenterol Hepatol. 2013;10:585-95.

  12. Freeman HJ. Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn’s disease. Can J Gastroenterol. 2005;19(10):603-6.

  13. Tavarela-Veloso F. Review article: skin complications associated with inflammatory bowel disease. Aliment Pharmacol Ther. 2004;4:50.

  14. Trost LB, McDonnell JK. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J. 2005;81(959):580-5.

  15. Jose FA, Heyman MB. Extraintestinal manifestations of inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2008;46(2):124-33.

  16. Georgiou S, Pasmatzi E, Monastirli A, Tsambaos D. Cutaneous manifestations of inflammatory bowel disease. Hosp Chron. 2006;1:158-68.

  17. Lebwohl M, Lebwohl O. Cutaneous manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 1998;4(2):142-8.

  18. Timani S, Mutasim DF. Skin manifestations of inflammatory bowel disease. Clin Dermatol. 2008;26(3):265-73.

  19. Ardizzone S, Puttini PS, Cassinotti A, Porro GB. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis. 2008;40 Suppl 2:S253-9.

  20. Mert A, Ozaras R, Tabak F, Pekmezci S, Demirkesen C, Ozturk R. Erythema Nodosum: An Experience of 10 Years. Scand J Infect Dis. 2004; 36(6-7):424-7.

  21. Goudet P, Dozois RR, Kelly KA, Ilstrup DM, Phillips SF. Characteristics and evolution of extraintestinal manifestations associated with ulcerative colitis after proctocolectomy. Dig Surg. 2001;18(1):51-5.

  22. Lakatos PL, Lakatos L, Kiss LS, Peyrin-Biroulet L, Schoepfer A, Vavricka S. Treatment of extraintestinal manifestations in inflammatory bowel disease. Digestion. 2012;86 Suppl 1:28-35.

  23. Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O. The effect of infliximab on extraintestinal manifestations of Crohn’s disease. Rheumatol Int. 2005;25(6):406-10.

  24. Field EA, Allan RB. Review article: oral ulceration – aetiopathogenesis, clinical diagnosis and management in the gastrointestinal clinic. Aliment Pharmacol Ther. 2003;18:949-62.

  25. Danese S, Semeraro S, Papa A, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005;11:7227-36.

  26. Patil SA, Cross RK. Update in the management of extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep. 2013;15(3):314.

  27. Letsinger JA, McCarty MA, Jorizzo JL. Complex aphthosis: a large case series with evaluation algorithm and therapeutic ladder from topicals to thalidomide. J Am Acad Dermatol. 2005;52(3 Pt 1):500-8.

  28. Al Roujayee A. Cutaneous manifestations of inflammatory bowel disease. Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association. 2007;13:159-62.

  29. Neesse A, Michl P, Kunsch S, Ellenrieder V, Gress TM, Steinkamp M. Simultaneous onset of ulcerative colitis and disseminated pyoderma gangrenosum. Case Rep Gastroenterol. 2007;1(1):110-5.

  30. Veloso FT. Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome? World J Gastroenterol. 2011;17(22):2702-7.

  31. Su W, Davis MD, Weenig RH, et al. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol. 2004;43:790-800.

  32. Zippi M, Pica R, De Nitto D, Paoluzi P. Biological therapy for dermatological manifestations of inflammatory bowel disease. World J Clin Cases. 2013;1(2):74-8.

  33. Callen JP. Pyoderma gangrenosum. Lancet. 1998;351(9102):581-5.

  34. Marzano AV, Ishak RS, Saibeni S, Crosti C, Meroni PL, Cugno M. Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet’s syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol. 2013; 45(2):202-10.

  35. Patel F, Fitzmaurice S, Duong C, et al. Effective strategies for the management of pyoderma gangrenosum: a comprehensive review. Acta Derm Venereol. 2015;95(5):525-31.

  36. Hegarty AM, Barrett AW, Scully C. Pyostomatitis Vegetans. Clin Exp Dermatol. 2004;29(1):1-7.

  37. Femiano F, Lanza A, Buonaiuto C, Perillo L, Dell’Ermo A, Cirillo N. Pyostomatitis vegetans: a review of the literature. Med Oral Patol Oral Cir Bucal. 2009;14(3):E114-7.

  38. Guhl G, Garcia-Diez A. Subcutaneous sweet syndrome. Dermatol Clin. 2008;26(4):541-51, viii-ix.

  39. Ytting H, Vind I, Bang D, Munkholm P. Sweet’s syndrome--an extraintestinal manifestation in inflammatory bowel disease. Digestion. 2005;72 (2-3):195-200.

  40. Ali M. Ulcerative colitis and Sweet’s syndrome: a case report and review of the literature. Can J Gastroenterol. 2008;22:296.

  41. Cohen PR, Kurzrock R. Sweet’s syndrome revisited: a review of disease concepts. Int J Dermatol. 2003;42(10):761-78.

  42. Bouguen G, Siproudhis L, Bretagne JF, Bigard MA, Peyrin-Biroulet L. Nonfistulizing perianal Crohn’s disease: clinical features, epidemiology, and treatment. Inflamm Bowel Dis. 2010;16(8):1431-42.

  43. Ghazi LJ, Schwartz DA. Perianal Crohn’s Disease—A Gastroenterologist’s Perspective. Semin Colon Rectal Surg. 2012;23(3):117- 124.

  44. Gligorijevic V, Spasic ´ N, Bojic ´ D, et al. The role of pelvic MRI in assesment of combined surgical and infliximab treatment for perianal Crohn’s disease. Acta Chir Iugosl. 2010;57(3):89-95.

  45. Schwartz DA, Wiersema MJ, Dudiak KM, et al. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn’s perianal fistulas. Gastroenterology. 2001;121(5):1064-72.

  46. Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn’s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 2003;9(2):98-103.

  47. Sands BE, Bernstein CN, Chey WY, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876-85.

  48. Vaid RM, Cohen BA. Cutaneous Crohn’s disease in the pediatric population. Pediatr Dermatol. 2010;27(3):279-81.

  49. Barret M, de Parades V, Battistella M, Sokol H, Lemarchand N, Marteau P. Crohn’s disease of the vulva. J Crohns Colitis. 2014;8(7):563-70.

  50. Rigopoulos D, Larios G, Katsambas A. Skin signs of systemic diseases. Clin Dermatol. 2011;29(5):531-40.

  51. Rahier JF, Buche S, Peyrin-Biroulet L, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8(12):1048- 55.

  52. Ramiscal J, Brewer J. Thiopurines and risk of nonmelanoma skin cancer in inflammatory bowel disease. JAMA Dermatol. 2013;149:92.




2020     |     www.medigraphic.com